Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,239 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline Solution - IV Clear all
Withdrawn Early Phase 1 Interventional

Melphalan on Disease Burden Measured by Next Generation Sequencing Before AHCT (Autologous Hematopoietic Cell Transplant) for Multiple Myeloma

NCT05013437
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Evomela, Next Generation Sequencing, Prochlorperazine, Acetaminophen, Diphenhydramine
Drug · Device
Lead sponsor
Koen van Besien
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

Prevention of Post Operative Bone Loss in Children

NCT00655681
View directory record Official record
Conditions
Osteoporosis, Cerebral Palsy, Spina Bifida, Osteopenia, Osteogenesis Imperfecta
Interventions
pamidronate, saline
Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
4 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Results available

Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia

NCT01161121
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
adenosine, regadenoson
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Jacksonville, Florida • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 19, 2026, 8:02 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency

NCT03733067
View directory record Official record
Conditions
CTLA4 Haploinsufficency, Chronic Cytopenia
Interventions
abatacept, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)

NCT03094663
View directory record Official record
Conditions
Knee Arthropathy
Interventions
Bupivacaine with epinephrine, Methylprednisolone, Cefazolin, 8 MHz. Chiba needle, Bupivacaine with Dexamethasone, Bupivacaine 25cc, Bupivacaine 20cc, Dexamethasone
Drug · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor

NCT02989571
View directory record Official record
Conditions
Labor; Forced or Induced, Affecting Fetus or Newborn
Interventions
Intravenous normal saline administered at 250ml/hr, Intravenous normal saline administered at 125ml/hr
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional Results available

Maxigesic IV Phase 3 Bunionectomy Study

NCT02689063
View directory record Official record
Conditions
Post Operative Pain
Interventions
Maxigesic IV, IV Acetaminophen, IV Ibuprofen, Placebo IV
Drug
Lead sponsor
AFT Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Pasadena, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Phase 2 Interventional

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

NCT06067438
View directory record Official record
Conditions
Atrial Fibrillation, Esophageal Carcinoma
Interventions
Amiodarone Hydrochloride, Saline
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

NCT04210115
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
Interventions
pembrolizumab, placebo, cisplatin, 5-FU, radiotherapy, leucovorin, levoleucovorin, oxaliplatin
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

NCT00889538
View directory record Official record
Conditions
Autism, Severe Behavior Disorder
Interventions
placebo, glutathione, glutathione, vit C and NAC
Drug
Lead sponsor
University of Louisville
Other
Eligibility
5 Years to 16 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Ketamine in Adults With Obsessive-Compulsive Disorder (OCD)

NCT01100255
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine infusion, Saline
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2017 · Synced Oct 19, 2026, 8:02 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358
View directory record Official record
Conditions
Breast Neoplasms
Interventions
pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 2 Interventional

Use of Ketamine Prior to Cardiopulmonary Bypass in Children

NCT00556361
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
saline, ketamine
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2007 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Early Phase 1 Interventional

Combined IV and Topical TXA in Major Spine Surgery

NCT04797156
View directory record Official record
Conditions
Spine Surgery, Back Pain
Interventions
High Dose Tranexamic acid, Low Dose Tranexamic acid, Tranexamic acid Topical, Normal saline
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

3-D Transcranial Ultrasound Analysis Study

NCT00239525
View directory record Official record
Conditions
Cerebrovascular Accident, Intracranial Hypertension
Interventions
3-D ultrasound scanner, Perflutren Protein-Type A Microspheres for injection
Device · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

NCT02332889
View directory record Official record
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional Results available

A Dose Ranging Effect of Preoperative Diphenhydramine on Postoperative Quality of Recovery After Ambulatory Surgery

NCT01451762
View directory record Official record
Conditions
Surgery, Pain
Interventions
.9 normal saline, 25 mg diphenhydramine IV, 50 mg diphenhydramine IV
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 14, 2014 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Not applicable Interventional

Restrictive Intravenous Fluids Trial in Sepsis

NCT03137446
View directory record Official record
Conditions
Septic Shock, Severe Sepsis
Interventions
Intravenous Fluid Cap
Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ketamine, Nicotine, Placebo, Ketamine and Nicotine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Oct 19, 2026, 8:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD

NCT02956122
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
GLASSIA, methylprednisolone or equivalent steroid, Albumin
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional

Premedication for Less Invasive Surfactant Administration Study (PRELISA)

NCT05065424
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
IV Atropine and Fentanyl Premedication Arm, IV Normal Saline Placebo Arm
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
0 Hours to 72 Hours
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Impact of Prophylactic Ephedrine on Fetal Heart Tracing and Uterine Tetanic Contraction After CSE

NCT05873218
View directory record Official record
Conditions
Labor
Interventions
Ephedrine, Normal Saline Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 19, 2026, 8:02 AM EDT
Completed Phase 4 Interventional Results available

Steroids in Bilateral Total Knee Replacement

NCT01399268
View directory record Official record
Conditions
Postoperative Inflammatory Response
Interventions
Hydrocortisone, Saline
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 19, 2026, 8:02 AM EDT